CN115386105A - 多重酶活性纳米酶荧光水凝胶的制备方法及应用 - Google Patents
多重酶活性纳米酶荧光水凝胶的制备方法及应用 Download PDFInfo
- Publication number
- CN115386105A CN115386105A CN202211028903.1A CN202211028903A CN115386105A CN 115386105 A CN115386105 A CN 115386105A CN 202211028903 A CN202211028903 A CN 202211028903A CN 115386105 A CN115386105 A CN 115386105A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- cds
- gox
- solution
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 105
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 32
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229910052802 copper Inorganic materials 0.000 claims abstract description 59
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 53
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 47
- 229940088598 enzyme Drugs 0.000 claims abstract description 39
- 239000000499 gel Substances 0.000 claims abstract description 24
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 18
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 17
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920001661 Chitosan Polymers 0.000 claims abstract description 11
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 11
- 239000000661 sodium alginate Substances 0.000 claims abstract description 11
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 11
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052709 silver Inorganic materials 0.000 claims abstract description 7
- 239000004332 silver Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 18
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 15
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 12
- 239000012498 ultrapure water Substances 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 101710134784 Agnoprotein Proteins 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 229910017489 Cu I Inorganic materials 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 238000000703 high-speed centrifugation Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 229910001309 Ferromolybdenum Inorganic materials 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 30
- 208000027418 Wounds and injury Diseases 0.000 abstract description 30
- 102000003992 Peroxidases Human genes 0.000 abstract description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 14
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 14
- 108040007629 peroxidase activity proteins Proteins 0.000 abstract description 14
- 102000016938 Catalase Human genes 0.000 abstract description 11
- 108010053835 Catalase Proteins 0.000 abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 10
- 239000008103 glucose Substances 0.000 abstract description 10
- 238000010523 cascade reaction Methods 0.000 abstract description 9
- 230000035876 healing Effects 0.000 abstract description 8
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000004132 cross linking Methods 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 2
- 101100229716 Aspergillus niger gox gene Proteins 0.000 abstract 1
- 101100392469 Escherichia coli (strain K12) glcD gene Proteins 0.000 abstract 1
- 101100392473 Escherichia coli (strain K12) glcE gene Proteins 0.000 abstract 1
- 101100282781 Escherichia coli (strain K12) glcF gene Proteins 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000003278 mimic effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- -1 hydroxyl radicals Chemical class 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000002789 catalaselike Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0073—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form semi-solid, gel, hydrogel, ointment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/08—Metals
- C08K2003/0806—Silver
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/16—Halogen-containing compounds
- C08K2003/162—Calcium, strontium or barium halides, e.g. calcium, strontium or barium chloride
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/04—Carbon
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/08—Metals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种多重酶活性纳米酶荧光水凝胶的制备方法，该方法由银纳米Cu,I@AgNPs与Mo,Fe‑CDs组成纳米酶Mo,Fe/Cu,I@Ag，并将葡萄糖氧化酶与该纳米酶负载到水凝胶上；利用水凝胶表现出的GOx、拟过氧化物酶、拟过氧化氢酶和拟超氧化物歧化酶活性与pH响应葡萄糖引发的级联反应用于糖尿病创面愈合；利用含Mo,Fe/Cu,I@Ag@GOx纳米酶通过Ca2+交联海藻酸钠和壳聚糖构建的水凝胶具有可注射性、力学和黏附性以及荧光性质和有益的生物相容性；重要的是，纳米酶凝胶可溶于水或乙醇，在用作敷料时不会对伤口造成二次损伤，本发明水凝胶具有高效促血管生成、细菌感染创面愈合和原位监测等特点。
Description
技术领域
本发明涉及纳米材料抗菌技术领域，具体为一种多重酶活性纳米酶荧光水凝胶的制备方法及应用。
背景技术
糖尿病创面由于具有持续的葡萄糖积累、持续的细菌感染、受损的血管生成导致创面缺氧和氧化应激等特点，导致创面的慢性愈合。有研究报道基于葡萄糖氧化酶（GOx）和过氧化物酶（POD）的葡萄糖激活级联反应，通过解决高血糖和细菌感染促进伤口修复。GOx与葡萄糖作用产生过氧化氢（H2O2）和葡萄糖醛酸，使伤口部位的pH降低到3~4，提供了POD反应的条件，H2O2通过模拟POD的活性进一步催化生成羟基自由基（·OH），导致葡萄糖消耗和细菌死亡。这样就规避了直接使用有毒的H2O2，以克服pH对拟POD活性的限制。拟超氧化物歧化酶（SOD）纳米酶能将超氧自由基（O2 ·-）转化为H2O2和O2，清除O2 ·-。拟过氧化氢酶（CAT）纳米酶能将H2O2转化为O2，减轻氧化应激和缺氧，使皮肤再生。具有多重模拟酶活性的纳米酶在糖尿病伤口愈合中有非常好的促伤口愈合作用。碳点（CDs）是一种10nm以下超小尺寸的零维纳米材料，由于其优异的光学性能、水溶特性，特别是良好的生物相容性等特点，在抗菌治疗方面具有巨大的潜力。最近的研究表明，金属掺杂碳点会导致POD类催化过程中活性位点的利用率提高，这种杂原子掺杂不仅可以改变CDs的内部电子环境，可以提供活性位点，赋予CDs新的功能。CDs大都具有拟POD活性，很少有研究报道CDs纳米材料具有三重模拟酶活性（包括拟POD、CAT和SOD）。
发明内容
本发明提供了一种多重酶活性纳米酶荧光水凝胶的制备方法，该方法利用了纳米酶的多重纳米酶活性，结合GOx，负载于水凝胶中，利用级联反应，用于糖尿病伤口愈合。
本发明制备了一种由Cu-I掺杂碳点（Cu,I-CDs）还原硝酸银为银纳米（Cu,I@Ag）与Mo、Fe掺杂碳点（Mo,Fe-CDs）组成的具有多酶类活性纳米酶（Mo,Fe/Cu,I@Ag），并将葡萄糖氧化酶（GOx）与该纳米酶负载到水凝胶上，利用水凝胶表现出的GOx、拟过氧化物酶（POD）、拟过氧化氢酶（CAT）和拟超氧化物歧化酶（SOD）活性与pH响应葡萄糖引发的级联反应用于糖尿病创面愈合。第一个级联反应，由GOx引发，纳米酶水凝胶催化葡萄糖和O2转化为葡萄糖酸和H2O2，在POD作用下生成羟基自由基（·OH）来根除细菌；第二个级联反应是，随着创面pH值的变化，碱性微环境发生变化，纳米酶水凝胶模拟SOD将O2 ·-转化为O2和H2O2，再通过拟CAT机制将内源性和外源性H2O2分解成O2，减轻氧化应激，缓解缺氧，促进糖尿病创面愈合；利用Mo,Fe/Cu,I@Ag@GOx纳米酶，通过Ca2+交联海藻酸钠（SA）和壳聚糖（CS）构建的水凝胶具有可注射性、力学和黏附性以及荧光性质和有益的生物相容性；重要的是，纳米酶水凝胶可溶于水或乙醇，在用作敷料时不会对伤口造成二次损伤；多功能荧光水凝胶具有高效促血管生成、促细菌感染创面愈合和原位监测等特点。
本发明多重酶活性纳米酶荧光水凝胶的制备如下：
（1）钼铁掺杂碳点（Mo,Fe-CDs）的合成：称取1.1-1.5g Na2MoO4、1.3-1.5gFeCl3.6H2O、0.03-0.05g多巴胺、2.1-2.5g柠檬酸及0.05-0.1g乙二胺溶于30-40mL超纯水中，超声处理15-20分钟，将溶液转移至聚四氟乙烯内衬不锈钢反应器中，置于马弗炉中，在200℃反应10-12小时，反应完成后自然冷却至室温，得棕色溶液；将棕色溶液用0.22μm滤膜除去大颗粒杂质，再经高速离心，上清液真空干燥，得到Mo,Fe-CDs；
（2）Cu,I掺杂碳点（Cu,I-CDs）的合成：称取0.1-0.3g CuCl2、1.3-1.5mmol/L3-碘-L-酪氨酸及0.1-0.5g乙二胺溶于40-50mL超纯水中，超声处理15-20分钟，将溶液转移至聚四氟乙烯内衬不锈钢反应器中，置于马弗炉中，在180℃反应8-10小时，反应完成后自然冷却至室温，得棕色溶液；将棕色溶液用0.22μm滤膜除去大颗粒杂质，再经高速离心，上清液真空干燥，得到Cu,I-CDs；
（3）银纳米Cu,I@Ag合成：将10-15mg的Cu,I-CDs溶于30mL超纯水中，加入AgNO3，AgNO3在混合液中的浓度为20-25mg/mL，避光搅拌30-60分钟，高速离心，胶体用去离子水洗涤3次，移出多余的Cu,I-CDs和AgNO3，冷冻干燥，得到银纳米Cu,I@Ag；
（4）Mo,Fe/Cu,I@Ag合成：将Mo,Fe-CDs 与Cu,I@Ag按重量比1:1-3的比例加入到超纯水中，混合溶液室温搅拌24小时，高速离心，上清液60℃真空干燥12-24小时制得Mo,Fe/Cu,I@Ag；
（5）Mo,Fe/Cu,I@Ag@GOx水凝胶的合成：将0.5-1.0g海藻酸钠（SA）加入到7-10mL甘油和5-10mL 浓度1-5mg/mLMo,Fe/Cu,I@Ag的混合液中，搅拌混合1-2小时后，加入质量浓度0.8-1.2%的壳聚糖（CS）溶液10-15mL、葡萄糖氧化酶（GOx）0.125-0.5mg和质量浓度1-3%的CaCl2溶液200-500μL，溶胶-凝胶转变24小时，得到Mo,Fe/Cu,I@Ag@GOx水凝胶。
步骤（1）-（4）中高速离心是在10000r/min下处理15-20分钟。
本发明另一目的是将上述方法制得的多重酶活性纳米酶荧光水凝胶应用在制备糖尿病伤口愈合试剂中。
本发明的优点在于：
1、本发明利用纳米酶具有三重模拟酶，包括POD、CAT和SOD活性的特性，将其与天然GOx负载于水凝胶中，在用于糖尿病伤口治疗时，发生级联反应，第一个级联反应，由GOx引发，纳米酶凝胶催化葡萄糖和O2转化为葡萄糖酸和H2O2，POD催化H2O2羟基自由基（·OH）来根除细菌；第二个级联反应是，随着创面pH值的变化，碱性微环境发生变化，纳米酶凝胶模拟SOD将O2 ·-转化为O2和H2O2，通过拟CAT机制将内源性和外源性H2O2分解成O2，减轻氧化应激，缓解缺氧，促进糖尿病创面愈合；
2、利用含Mo,Fe/Cu,I@Ag@GOx纳米酶通过Ca2+交联海藻酸钠（SA）和壳聚糖（CS）构建的水凝胶具有可注射性、力学和黏附性以及荧光性质和有益的生物相容性；
3、纳米酶水凝胶可溶于水或乙醇，在用作敷料时不会对伤口造成二次损伤，多功能荧光水凝胶具有高效促血管生成、细菌感染创面愈合和原位监测等特点；
本发明水凝胶制备工艺简单，适用于工业化生产和市场推广应用。
附图说明
图1为不同水凝胶氧化TMB（POD活性）的紫外可见吸收光谱图，图中（1）为单独TMB，不添加水凝胶的空白对照，（2）Mo,Fe-CDs@GOx水凝胶，（3）Cu,I@Ag@GOx水凝胶，（4）Mo,Fe/Cu,I@Ag@GOx水凝胶；
图2为不同水凝胶过氧化氢酶（CAT）活性结果示意图，图中（1）为不添加水凝胶的空白对照，（2）Mo,Fe-CDs@GOx水凝胶，（3）Cu,I@Ag@GOx水凝胶，（4）Mo,Fe/Cu,I@Ag@GOx水凝胶；
图3为不同水凝胶拟超氧化物歧化酶（SOD）活性结果示意图，图中（1）为不添加水凝胶的空白对照，（2）Mo,Fe-CDs@GOx水凝胶，（3）Cu,I@Ag@GOx水凝胶，（4）Mo,Fe/Cu,I@Ag@GOx水凝胶；
图4为水凝胶的荧光性能图，上图为自然光下的状态，下图为紫外光下的状态；Mo,Fe-CDs gel为Mo,Fe-CDs@GOx水凝胶，Cu,I@Ag gel为Cu,I@Ag@GOx水凝胶，Mo,Fe/Cu,I@Aggel为Mo,Fe/Cu,I@Ag@GOx水凝胶；
图5为水凝胶的注射性能图；
图6为水凝胶的粘附性能图；
图7为水凝胶的自愈性能图；
图8为水凝胶溶解性图；
图9水凝胶的含水量结果，图中水凝胶基底为不添加Mo,Fe/Cu,I@Ag@GOx纳米酶制得的凝胶，Mo,Fe-CDs水凝胶为Mo,Fe-CDs@GOx水凝胶，Cu,I@Ag水凝胶为Cu,I@Ag@GOx水凝胶；
图10为本发明水凝胶细胞毒性实验结果；
图11为不同水凝胶抗菌实验结果，图中Mo,Fe-CDs gel为Mo,Fe-CDs@GOx水凝胶，Cu,I@Ag gel为Cu,I@Ag@GOx水凝胶；
图12为水凝胶对糖尿病小鼠伤口愈合照片；
图13为水凝胶对糖尿病小鼠伤口愈合率统计结果。
具体实施方式
下面将结合具体的实施例对本发明的技术方案作进一步详细地描述说明，但本发明的保护范围并不仅限于此。
实施例1：多重酶活性纳米酶的制备及性能
（1）称取1.2g Na2MoO4、1.3gFeCl3.6H2O、0.03g多巴胺、2.2g柠檬酸及0.06g乙二胺溶于35mL超纯水中，超声处理15分钟，将溶液转移至聚四氟乙烯内衬不锈钢反应器中，置于马弗炉中，200℃反应10小时，反应完成后自然冷却至室温，得棕色溶液；将棕色溶液用0.22μm滤膜除去大颗粒杂质，再在10000r/min下离心15分钟，上清液真空干燥，得到钼铁掺杂碳点Mo,Fe-CDs；
（2）称取0.2g CuCl2、1.3mmol/L 3-碘-L-酪氨酸及0.2g乙二胺溶于40mL超纯水中，超声处理20分钟，将溶液转移至聚四氟乙烯内衬不锈钢反应器中，置于马弗炉中，180℃反应10小时，反应完成后自然冷却至室温，得棕色溶液；将棕色溶液用0.22μm滤膜除去大颗粒杂质，再在10000r/min下离心15分钟，上清液真空干燥，得到Cu,I掺杂碳点Cu,I-CDs；
（3）银纳米Cu,I@Ag合成：将10mg的Cu,I-CDs溶于30mL超纯水中，加入AgNO3，AgNO3在混合液中的浓度为20mg/mL，避光搅拌40分钟，在10000r/min下离心15分钟，胶体用去离子水洗涤3次，移出多余的Cu,I-CDs和AgNO3，冷冻干燥，得到银纳米Cu,I@Ag；
（4）按1:2de 重量比，将Mo,Fe-CDs与Cu,I@Ag加入到超纯水中，混合溶液室温搅拌24小时，在10000r/min下离心15分钟，上清液60℃真空干燥15小时制得Mo,Fe/Cu,I@Ag；
（5）将0.6g海藻酸钠（SA）加入到8mL甘油和6mL浓度2mg/mLMo,Fe/Cu,I@Ag的混合液中，搅拌混合1小时后，加入10mL壳聚糖（CS，1%）、葡萄糖氧化酶（GOx，0.2mg）和250μLCaCl2溶液（2%），溶胶-凝胶转变24小时，得到Mo,Fe/Cu,I@Ag@GOx水凝胶；
（6）采用TMB显色反应测定水凝胶的拟过氧化酶（POD）活性
将100µg/mL 水凝胶100μL、100mmol/L的TMB 50µL、10mmol/L H2O250 μL加入到pH4.5醋酸盐缓冲溶液2mL中，充分混匀，室温孵育10分钟后，离心分离，取上层清液用紫外-可见分光光度计在655nm处测量吸光度，每个样品测量3次，取平均值，结果如图1；从图1中可以看出，在酸性条件下，本实施例制得的水凝胶表现出相当高的拟POD活性；图1中Mo,Fe-CDs水凝胶、Cu,I-CDs水凝胶是在步骤（5）制备过程中用Mo,Fe-CDs、Cu,I-CDs替换Mo,Fe/Cu-I@Ag制得的水凝胶；
（7）采用 TiCl4显色反应测定水凝胶的拟过氧化氢酶（CAT）活性
将100µg/mL水凝胶100μL与1mL、50mmol/L的 H2O2反应10分钟，加入200μL10%TiCl4，充分混匀，室温孵育10分钟后，离心分离，取上层清液用紫外-可见分光光度计在415nm处测量吸光度，每个样品测量3次，取平均值；
结果如图2；从图2中可以看出，本实施例制得的水凝胶表现出好的拟过氧化氢酶活性。
（8）采用氯化硝基蓝四氮唑（NBT）显色反应测定水凝胶的拟超氧歧化物酶（SOD）活性
将100µg/mL水凝胶100μL加入到5mg/mL NBT100μL 和pH=3磷酸盐缓冲液的混合物中，反应15min后，在580nm处测定吸光度，每个样品测量3次，取平均值，结果如图3；从图3中可以看出，本实施例制得的水凝胶表现出相当高的拟SOD活性。
（9）水凝胶的性能测试
参照文献（Shengbo Li等，Calcium ion cross-linked sodium alginatehydrogels containingdeferoxamine and copper nanoparticles for diabetic woundhealing.International Journal of Biological Macromolecules 202 (2022) 657–670）中方法进行含水量测定，水凝胶的湿重（W湿）和在真空环境中冻干12小时后的干重（W干），根据以下公式计算水凝胶的含水量：含水量（%）=（W湿− W干）/ W湿× 100%；结果如图9所示，Mo,Fe/Cu,I@Ag@GOx水凝胶含有95%的水。
以下菌种分别从北纳创联生物科技有限公司、云南大学微生物研究所及昆明理工大学生命科学与技术学院获得；
实验方法：以金黄色葡萄球菌(S.aureus，ATCC25923)和铜绿假单胞菌(P.aeruginosa，ATCC27853)为实验菌株。采用平板计数法，通过计数CFU数来判定水凝胶的抗菌性能。首先，将上述菌种在固体Luria-Bertani（LB）培养基和固体营养肉汤培养基孵育24小时，用接种环挑取少量形成的菌落，接种到对应液体培养基（5mL）中，然后，在37℃、180rpm恒温摇床下震荡孵育12小时后，即获得细菌悬浮液（1×108 CFU/mL），用无菌磷酸盐缓冲液（PBS）稀释到1×105 CFU/mL。
实验材料分为四组：空白对照组、Mo,Fe-CDs@GOx水凝胶组、Cu,I-Ag@GOx水凝胶组和Mo,Fe/Cu,I@Ag@GOx水凝胶组，将培养的细菌加入磷酸盐缓冲液中作为空白对照组，其他组将培养的细菌与不同水凝胶混合，水凝胶浓度为100μg/mL，然后在37℃下将孵育60分钟，菌悬液经过稀释后（100μL）均匀涂布在LB固体培养基和营养肉汤固体培养基上，在37℃下培养24小时，计算菌落数，判断抗菌性能。
结果如图11所示，空白对照组几乎没有抗菌性能，Mo,Fe-CDs@GOx水凝胶组对铜绿假单胞菌和金黄色葡萄球菌杀菌率分别为27.3%、37.1%、Cu,I-Ag@GOx水凝胶组对铜绿假单胞菌和金黄色葡萄球的抗菌率分别为57.4%和60.1 %，Mo,Fe/Cu,I@Ag@GOx水凝胶对铜绿假单胞菌和金黄色葡萄球菌有近100%的杀菌率。
（9）小鼠伤口愈合试验
糖尿病小鼠及背部创面模型构建：所有动物实验均符合《动物护理指导原则》。选取6~8周龄、体重18~20g的雄性ICR小鼠作为实验动物。糖尿病伤口准备步骤如下：小鼠喂高脂饲料2周，腹腔注射链脲佐菌素（50mg/kg），链脲佐菌素溶于枸橼酸盐缓冲液（pH4.5）中，每天1次，连续5次注射，1周后通过尾静脉注射法测定小鼠血糖水平。连续两周血糖水平高于16.7mmol/L的小鼠被鉴定为Ⅰ型糖尿病小鼠。接下来，用医用剪刀在乙醚麻醉的小鼠背部切开直径1cm的圆形手术伤口。然后，将100μL金黄色葡萄球菌或铜绿假单胞菌悬液（1×108 CFU/mL）均匀涂于创面，用纱布和医用胶带包扎。小鼠感染菌24小时后，随机分为4组（每组5只小鼠）：对照组、Mo,Fe-CDs@GOx水凝胶组、Cu,I@Ag@GOx水凝胶组和Mo,Fe/Cu,I@Ag@GOx水凝胶组，对照组在小鼠伤口处涂抹无菌PBS，其余凝胶组中水凝胶浓度为100μg/mL，采用注射器将上述各组水凝胶（各300μL）注到小鼠伤口处并涂抹均匀，每隔24小时更换一次小鼠创面上的水凝胶，在第0、1、3、5、7天测量小鼠创面情况，通过愈合率(%) = (A0 - At) /(A0×100)计算创面愈合率，其中A0为初始创面面积，At为各时间点的残余创面面积。
实验结果见图12、13，对照组于第1天出现脓液，持续至第7天，提示伤口感染，第7天，对照组的伤口变得更大，而Mo,Fe/Cu,I@Ag@GOx水凝胶组创面面积明显减少，创面愈合率90.15%，在其他治疗组创面面积中最高，创面基本愈合，
以上结果表明，本发明制备的纳米酶水凝胶有多重酶活性，通过级联反应起到抗菌、提供氧及清除自由功能，使具有糖尿小鼠伤口具有好的愈合效果，同时在凝胶好的粘附性能，生物相容性、抗菌性能及伤口愈合性能，其溶解性能在用作敷料时不会对伤口造成二次损伤，多功能荧光水凝胶具有高效促血管生成、细菌感染创面愈合和原位监测等特点。
Claims (3)
1.一种多重酶活性纳米酶荧光水凝胶的制备方法，其特征在于，步骤如下：
（1）钼铁掺杂碳点Mo,Fe-CDs的合成
称取1.1-1.5g Na2MoO4、1.3-1.5gFeCl3.6H2O、0.03-0.05g多巴胺、2.1-2.5g柠檬酸及0.05-0.1g乙二胺溶于30-40mL超纯水中，超声处理15-20分钟后，在马弗炉中200℃下反应10-12小时，反应完成后自然冷却至室温，得棕色溶液；将棕色溶液用0.22μm滤膜除去大颗粒杂质，再经高速离心，上清液真空干燥，即得Mo,Fe-CDs；
（2）Cu,I掺杂碳点Cu,I-CDs的合成
称取0.1-0.3g CuCl2、1.3-1.5mmol/L3-碘-L-酪氨酸及0.1-0.5g乙二胺溶于40-50mL超纯水中，超声处理15-20分钟后置于马弗炉中，180℃反应8-10小时，反应完成后自然冷却至室温，得棕色溶液；将棕色溶液用0.22μm滤膜除去大颗粒杂质，再经高速离心，上清液真空干燥，得到Cu,I-CDs；
（3）银纳米Cu,I@Ag合成
将10-15mg的Cu,I-CDs置于30mL超纯水中，加入AgNO3，AgNO3在混合液中的浓度为20-25mg/mL，避光搅拌30-60分钟，高速离心，胶体用去离子水洗涤3次，移出多余的Cu,I-CDs和AgNO3，冷冻干燥，得到银纳米Cu-I@Ag；
（4）Mo,Fe/Cu-I@Ag合成
按重量比1:1-3的比例，将Mo,Fe-CDs与Cu,I@Ag加入到超纯水中，混合溶液室温搅拌24小时，高速离心，取上清液60℃下真空干燥12-24小时制得Mo,Fe/Cu,I@Ag；
（5）Mo,Fe/Cu,I@Ag@GOx水凝胶的合成
将0.5-1.0g海藻酸钠加入到7-10mL甘油和5-10mL浓度1-5mg/mLMo,Fe/Cu,I@Ag的混合液中，搅拌混合1-2小时后，加入质量浓度0.8-1.2%的壳聚糖溶液10-15mL、葡萄糖氧化酶0.125-0.5mg和质量浓度1-3%的CaCl2溶液200-500μL，溶胶-凝胶转变24小时，得到Mo,Fe/Cu-I@Ag@GOx水凝胶。
2.根据权利要求1所述的多重酶活性纳米酶荧光水凝胶的制备方法，其特征在于：步骤（1）-（4）中高速离心是在10000r/min下处理15-20分钟。
3.权利要求1-2中任一项所述的多重酶活性纳米酶荧光水凝胶的制备方法制得的纳米酶荧光水凝胶在制备糖尿病伤口愈合试剂中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211028903.1A CN115386105B (zh) | 2022-08-26 | 2022-08-26 | 多重酶活性纳米酶荧光水凝胶的制备方法及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211028903.1A CN115386105B (zh) | 2022-08-26 | 2022-08-26 | 多重酶活性纳米酶荧光水凝胶的制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115386105A true CN115386105A (zh) | 2022-11-25 |
| CN115386105B CN115386105B (zh) | 2024-03-22 |
Family
ID=84121901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211028903.1A Active CN115386105B (zh) | 2022-08-26 | 2022-08-26 | 多重酶活性纳米酶荧光水凝胶的制备方法及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115386105B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671264A (zh) * | 2023-01-04 | 2023-02-03 | 云南伦扬科技有限公司 | 一种用于靶向光催化变形链球菌生物膜的级联纳米酶 |
| CN115715744A (zh) * | 2023-01-08 | 2023-02-28 | 云南伦扬科技有限公司 | 一种碳点基纳米酶抗菌抗氧化冻干面膜 |
| CN115888811A (zh) * | 2022-12-29 | 2023-04-04 | 云南省烟草质量监督检测站 | 纳米酶材料及其制备方法和应用、Pb2+离子的检测方法 |
| CN116370406A (zh) * | 2023-06-02 | 2023-07-04 | 云南伦扬科技有限公司 | 一种用于治疗痔疮纳米酶可注射水凝胶 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1791680A (zh) * | 2003-02-07 | 2006-06-21 | 安玛西亚生物科学（Sv）公司 | 用核酸或蛋白质进行亚微升级反应的方法和装置 |
| US20110276025A1 (en) * | 2010-05-05 | 2011-11-10 | Xiao Yu Wu | Implantable-glucose responsive insulin delivery device |
| KR20120072063A (ko) * | 2010-12-23 | 2012-07-03 | 한국원자력연구원 | 효소를 함유한 상처 또는 궤양 치료용 수화겔 및 이의 제조방법 |
| KR20160040883A (ko) * | 2014-10-06 | 2016-04-15 | 충남대학교산학협력단 | 글루코스 옥시데이즈가 도입된 형광 가교 폴리아크릴아마이드 하이드로젤, 이의 제조방법 및 이를 포함하는 센서 |
| CN105726463A (zh) * | 2015-12-09 | 2016-07-06 | 宁波大学 | 一种用于胰岛素精控释放的双响应双交联可注射水凝胶的制备方法及应用 |
| CN112105320A (zh) * | 2018-01-05 | 2020-12-18 | 犹他大学研究基金会 | 治疗近视进展 |
| CN113476645A (zh) * | 2021-07-19 | 2021-10-08 | 吉林大学 | 一种用于糖尿病创面修复的抗菌水凝胶敷料及其制备方法 |
| CN114470177A (zh) * | 2022-01-14 | 2022-05-13 | 重庆医科大学 | 新型铈介导的共组装多功能纳米酶(CHA@GOx)用于糖尿病创面治疗 |
| EP4019056A1 (en) * | 2020-12-23 | 2022-06-29 | Universitat Politècnica De Catalunya | Method to produce in situ self-assembled multifunctional nanocomposite hydrogel and its uses thereof |
| CN114767941A (zh) * | 2022-03-28 | 2022-07-22 | 同济大学 | 一种基于葡萄糖氧化酶/氨基酸金属配合物催化制备的酶复合体水凝胶及其制备方法 |
| WO2022170361A1 (en) * | 2021-02-05 | 2022-08-11 | The Regents Of The University Of California | One-touch fingertip sweat sensor and personalized data processing for reliable prediction of blood biomarker concentrations |
-
2022
- 2022-08-26 CN CN202211028903.1A patent/CN115386105B/zh active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1791680A (zh) * | 2003-02-07 | 2006-06-21 | 安玛西亚生物科学（Sv）公司 | 用核酸或蛋白质进行亚微升级反应的方法和装置 |
| US20110276025A1 (en) * | 2010-05-05 | 2011-11-10 | Xiao Yu Wu | Implantable-glucose responsive insulin delivery device |
| KR20120072063A (ko) * | 2010-12-23 | 2012-07-03 | 한국원자력연구원 | 효소를 함유한 상처 또는 궤양 치료용 수화겔 및 이의 제조방법 |
| KR20160040883A (ko) * | 2014-10-06 | 2016-04-15 | 충남대학교산학협력단 | 글루코스 옥시데이즈가 도입된 형광 가교 폴리아크릴아마이드 하이드로젤, 이의 제조방법 및 이를 포함하는 센서 |
| CN105726463A (zh) * | 2015-12-09 | 2016-07-06 | 宁波大学 | 一种用于胰岛素精控释放的双响应双交联可注射水凝胶的制备方法及应用 |
| CN112105320A (zh) * | 2018-01-05 | 2020-12-18 | 犹他大学研究基金会 | 治疗近视进展 |
| EP4019056A1 (en) * | 2020-12-23 | 2022-06-29 | Universitat Politècnica De Catalunya | Method to produce in situ self-assembled multifunctional nanocomposite hydrogel and its uses thereof |
| WO2022170361A1 (en) * | 2021-02-05 | 2022-08-11 | The Regents Of The University Of California | One-touch fingertip sweat sensor and personalized data processing for reliable prediction of blood biomarker concentrations |
| CN113476645A (zh) * | 2021-07-19 | 2021-10-08 | 吉林大学 | 一种用于糖尿病创面修复的抗菌水凝胶敷料及其制备方法 |
| CN114470177A (zh) * | 2022-01-14 | 2022-05-13 | 重庆医科大学 | 新型铈介导的共组装多功能纳米酶(CHA@GOx)用于糖尿病创面治疗 |
| CN114767941A (zh) * | 2022-03-28 | 2022-07-22 | 同济大学 | 一种基于葡萄糖氧化酶/氨基酸金属配合物催化制备的酶复合体水凝胶及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| BAGAL-KESTWAL, DR等: "Tamarindus indica seed-shell nanoparticles-silver nanoparticles-Ceratonia silique bean gum composite for copper-micro mesh grid electrode fabrication and its application for glucose detection in artificial salivary samples", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 189, 30 September 2021 (2021-09-30), pages 993 - 1007 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115888811A (zh) * | 2022-12-29 | 2023-04-04 | 云南省烟草质量监督检测站 | 纳米酶材料及其制备方法和应用、Pb2+离子的检测方法 |
| CN115671264A (zh) * | 2023-01-04 | 2023-02-03 | 云南伦扬科技有限公司 | 一种用于靶向光催化变形链球菌生物膜的级联纳米酶 |
| CN115671264B (zh) * | 2023-01-04 | 2023-03-07 | 云南伦扬科技有限公司 | 一种用于靶向光催化变形链球菌生物膜的级联纳米酶 |
| CN115715744A (zh) * | 2023-01-08 | 2023-02-28 | 云南伦扬科技有限公司 | 一种碳点基纳米酶抗菌抗氧化冻干面膜 |
| CN116370406A (zh) * | 2023-06-02 | 2023-07-04 | 云南伦扬科技有限公司 | 一种用于治疗痔疮纳米酶可注射水凝胶 |
| CN116370406B (zh) * | 2023-06-02 | 2023-08-15 | 云南伦扬科技有限公司 | 一种用于治疗痔疮纳米酶可注射水凝胶 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115386105B (zh) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115386105A (zh) | 多重酶活性纳米酶荧光水凝胶的制备方法及应用 | |
| Berndt et al. | Antimicrobial porous hybrids consisting of bacterial nanocellulose and silver nanoparticles | |
| Krisch et al. | Ethanol and acetic acid tolerance in free and immobilized cells of Saccharomyces cerevisiae and Acetobacter aceti | |
| CN115501335B (zh) | 光声增强多重酶活性纳米酶水凝胶的制备方法和应用 | |
| EP1660670A1 (en) | A method for the production of bacterial cellulose | |
| CN115227864B (zh) | 一种多功能纳米酶原位水凝胶的制备方法及应用 | |
| CN112957457B (zh) | 一种促进糖尿病伤口愈合的级联类酶纳米系统及其制备方法和应用 | |
| Zhang et al. | Hollow nanosphere-doped bacterial cellulose and polypropylene wound dressings: Biomimetic nanocatalyst mediated antibacterial therapy | |
| CN101423854A (zh) | 一种用褐藻胶裂解酶制备褐藻胶寡糖的方法 | |
| Wang et al. | Wound therapy via a photo-responsively antibacterial nano-graphene quantum dots conjugate | |
| Pourali et al. | Assessment of the cutaneous wound healing efficiency of acidic, neutral and alkaline bacterial cellulose membrane in rat | |
| JP2018524283A (ja) | 磁気固定化殺菌性酵素 | |
| CN110152055B (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
| CN111939270A (zh) | 一种具有持续抗菌效果的双纳米酶抗菌剂及其制备方法 | |
| Sulej et al. | Antimicrobial and antioxidative potential of free and immobilised cellobiose dehydrogenase isolated from wood degrading fungi | |
| CN115006586B (zh) | 一种纳米酶原位水凝胶的制备方法及应用 | |
| Mo et al. | Recent advances in nanozymes for bacteria-infected wound therapy | |
| Cotton et al. | The role of alginate in P. aeruginosa PAO1 biofilm structural resistance to gentamicin and ciprofloxacin | |
| CN101597381A (zh) | 一种用于针后贴的海藻酸钙复合膜医用敷料及其制备方法和应用 | |
| Zhu et al. | A multi-enzyme-like activity exhibiting mussel-inspired nanozyme hydrogel for bacteria-infected wound healing | |
| Razak et al. | Biotechnological production of fungal biopolymers chitin and chitosan: their potential biomedical and industrial applications | |
| CN104673702B (zh) | 一株弯曲乳酸杆菌（Lactobacillus crispatus）及其制药用途 | |
| CN102293689B (zh) | 一种纳米银睾丸假体 | |
| CN114931588B (zh) | 银纳米粒卡那霉素抗菌水凝胶的制备方法 | |
| CN114716817B (zh) | 一种二氧化铈纳米棒杂化多功能水凝胶、制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |